Development and in vivo evaluation of metabolically resistant antagonists of B1 receptors for kinins.
The B1 receptors for kinins are selectively stimulated by bradykinin (BK) and Lys-BK metabolites that do not have the C-terminal arginine, des-Arg9-BK and Lys-des-Arg9-BK, respectively. B1 receptors mediate a definite subset of the cardiovascular effects of kinins in normal and septic animals. We have studied the metabolism of the best selective B1 antagonist, Lys[Leu8]des-Arg9-BK, in order to support the rational design of new antagonists that have increased metabolic stability. The affinity of the new compounds was evaluated using the pA2 scale and was based on the antagonism of the contractile effect of kinins in the rabbit isolated aortic preparation. Acetylation of the alpha-amino group of the N-terminal Lys residue provided an excellent protection from the degradation by rabbit blood plasma. This and the inhibitory effect of amastatin on the metabolism of Lys[Leu8]des-Arg9-BK indicated that aminopeptidase M (AmM) is the major route of inactivation for this class of peptides in plasma. Various other modifications afforded a more or less complete resistance to purified angiotensin I converting enzyme (ACE). One analog, Ac-Lys[MeAla6, Leu8]des-Arg9-BK, was found resistant to the above-mentioned enzymes and to neutral endopeptidase-24.11 extracted from rabbit kidney. This antagonist, although 100 times less potent than the parent peptide Lys[Leu8]des-Arg9-BK on the rabbit aortic preparation, was equipotent in vivo against the hypotensive effect of a B1 agonist in lipopolysaccharide-treated rabbits, and unlike the original compound, its effect was persistent after the end of the infusion. Ac-Lys[MeAla6, Leu8]des-Arg9-BK does not antagonize B2 receptors either in vitro or in vivo.(ABSTRACT TRUNCATED AT 250 WORDS)
Centre de Recherche (Université Laval), Hôtel-Dieu de Québec, Canada.
G
G
Drapeau
R
R
Audet
L
L
Levesque
D
D
Godin
F
F
Marceau
D000595:Amino Acid Sequence; D000818:Animals; D001920:Bradykinin / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D004353:Drug Evaluation, Preclinical; D004355:Drug Stability; D005260:Female; D007609:Kallidin / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology; D007668:Kidney / Q000648:ultrastructure; D008297:Male; D008969:Molecular Sequence Data; D010447:Peptide Hydrolases / Q000378:metabolism; D011817:Rabbits; D018002:Receptors, Bradykinin; D017981:Receptors, Neurotransmitter / Q000037:antagonists & inhibitors* / Q000502:physiology; D013329:Structure-Activity Relationship
D018002:Receptors, Bradykinin; D017981:Receptors, Neurotransmitter; C082229:bradykinin, Lys-Leu(8)-desArg(9)-; C072121:bradykinin, Sar-(D-Phe(8))des-Arg(9); D007609:Kallidin; D010447:Peptide Hydrolases; D001920:Bradykinin